<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02416739</url>
  </required_header>
  <id_info>
    <org_study_id>Amina-X-002</org_study_id>
    <nct_id>NCT02416739</nct_id>
  </id_info>
  <brief_title>Anticancer Activity of Nicotinamide on Lung Cancer</brief_title>
  <official_title>Randomized Double-blinded Comparative Trial to Study the Add-on Activity of Combination Treatment of Nicotinamide on Progression Free Survival for EGFR Mutated Lung Cancer Terminal Stage Patients Being Treated With Gefitinib or Erlotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Il Yeong Park, Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chungbuk National University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nicotinamide is an inhibitor of human sirtuins (HDAC III), and is found to re-activate
      epigenetically silenced tumor suppressors, RUNX3 (runt-related gene 3) and others, in cancer
      cells. Nicotinamide was found to be effective in several animal cancer models including lung,
      bladder, liver, etc. The purpose of this study is to determine whether nicotinamide is also
      effective in the treatment of human lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard therapy to the EGFR (epidermal growth factor receptor) mutation positive
      non-small-cell lung cancer patients who are not eligible to operation is to administer
      EGFR-TKIs (tyrosine kinase inhibitors, gefitinib or erlotinib). To determine the
      effectiveness of nicotinamide on lung cancer, nicotinamide or placebo tablet will be
      co-administered with gefitinib or erlotinib for two years until the event or censoring
      occurs. The stratified block randomization was designed with 3 covariates (EGFR mutation
      status, kind of EGFR-TKI, ECOG (Eastern Cooperative Oncology Group) performance status score
      variation). The size of lesions will be checked every other months by radiology. PD
      (progressive disease) will be assessed according to RECIST(Response Evaluation Criteria in
      Solid Tumors)1.1. After observing 36 events, an interim analysis of hazard ratio by Cox
      proportional hazard regression will be performed. The final analysis will be done by the same
      protocol after observation of 72 events. The significance level of the interim and final
      analysis were set to 0.0075 and 0.0209 respectively. Response rate, quality of life (measured
      by 10 questions at every visit), and overall survival will be analysed together. All other
      adverse reactions will be analysed and reported, if there.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hazard ratio (PFS) of the nicotinamide arm to the placebo arm</measure>
    <time_frame>two year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>two year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>two year</time_frame>
    <description>measured by the cancer-related QOL questionaire scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>two year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Nicotinamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotinamide with EGFR-TKI:
gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day
nicotinamide (500mg tab) - per oral, twice a day, until the event or censoring occurs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet with EGFR-TKI:
gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day
placebo tablet - per oral, twice a day, until the event or censoring occurs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinamide</intervention_name>
    <description>Nicotinamide (1g/day) or placebo treatment is added to the standard drug treatment (gefitinib or erlotinib) to EGFR mutated NSCLC patients</description>
    <arm_group_label>Nicotinamide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Amina-X</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Operation-impossible stage 4 non-small-cell lung carcinoma (NSCLC), or recurred
             terminal stage NSCLC after previous operation or radiation therapy

          -  EGFR mutated (exon 19 deletion or L858R mutation)

          -  Life expectation more than 3 months

          -  More than 1 measurable lesions by RECIST 1.1 which were not exposed to radiation
             previously

          -  ECOG (Eastern Cooperative Oncology Group ) performance status grade 0~2

          -  Who signed the informed consent form

        Exclusion Criteria:

          -  Who had received chemotherapy or EGFR tyrosin kinase inhibitors previously, except
             whom had received operation at least 6 months ago and received supplementary
             chemotherapy

          -  Who has metastasized brain lesion that needs operation or radiation therapy

          -  Above grade 2, CTCAE (Common Toxicity Criteria for Adverse Effects) 4.0 criteria for
             blood, liver and kidney

          -  Who does Not agree to contraception

          -  Who has allergy to nicotinamide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Il Yeong Park, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Chungbuk National University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-Chul Kim, MD, PhD</last_name>
    <phone>+82-61-379-7614</phone>
    <email>kyc0923@jnu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Da Min Jeon, Nurse</last_name>
    <phone>+82-61-379-7851</phone>
    <email>damin2snub@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Chonnam</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Chul Kim, MD, PhD</last_name>
      <phone>+82-61-379-7614</phone>
      <email>kyc0923@jnu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Da Min Jeon, Nurse</last_name>
      <phone>+82-61-379-7851</phone>
      <email>damin2snub@naver.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Li QL, Kim HR, Kim WJ, Choi JK, Lee YH, Kim HM, Li LS, Kim H, Chang J, Ito Y, Youl Lee K, Bae SC. Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun. 2004 Jan 30;314(1):223-8.</citation>
    <PMID>14715269</PMID>
  </reference>
  <reference>
    <citation>Li QL, Ito K, Sakakura C, Fukamachi H, Inoue Ki, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002 Apr 5;109(1):113-24.</citation>
    <PMID>11955451</PMID>
  </reference>
  <reference>
    <citation>Avalos JL, Bever KM, Wolberger C. Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell. 2005 Mar 18;17(6):855-68.</citation>
    <PMID>15780941</PMID>
  </reference>
  <reference>
    <citation>Black JC, Mosley A, Kitada T, Washburn M, Carey M. The SIRT2 deacetylase regulates autoacetylation of p300. Mol Cell. 2008 Nov 7;32(3):449-55. doi: 10.1016/j.molcel.2008.09.018.</citation>
    <PMID>18995842</PMID>
  </reference>
  <reference>
    <citation>Lee YS, Lee JW, Jang JW, Chi XZ, Kim JH, Li YH, Kim MK, Kim DM, Choi BS, Kim EG, Chung JH, Lee OJ, Lee YM, Suh JW, Chuang LS, Ito Y, Bae SC. Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell. 2013 Nov 11;24(5):603-16. doi: 10.1016/j.ccr.2013.10.003.</citation>
    <PMID>24229708</PMID>
  </reference>
  <reference>
    <citation>Omar MF, Ito K, Nga ME, Soo R, Peh BK, Ismail TM, Thakkar B, Soong R, Ito Y, Salto-Tellez M. RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status. Pathol Oncol Res. 2012 Oct;18(4):783-92. Epub 2012 Jun 24.</citation>
    <PMID>22729835</PMID>
  </reference>
  <reference>
    <citation>Kim WJ, Lee JW, Quan C, Youn HJ, Kim HM, Bae SC. Nicotinamide inhibits growth of carcinogen induced mouse bladder tumor and human bladder tumor xenograft through up-regulation of RUNX3 and p300. J Urol. 2011 Jun;185(6):2366-75. doi: 10.1016/j.juro.2011.02.017. Epub 2011 Apr 21. Erratum in: J Urol. 2011 Aug;186(2):762.</citation>
    <PMID>21511279</PMID>
  </reference>
  <reference>
    <citation>Park SY, Lee KB, Lee MJ, Bae SC, Jang JJ. Nicotinamide inhibits the early stage of carcinogen-induced hepatocarcinogenesis in mice and suppresses human hepatocellular carcinoma cell growth. J Cell Physiol. 2012 Mar;227(3):899-908. doi: 10.1002/jcp.22799.</citation>
    <PMID>21503886</PMID>
  </reference>
  <reference>
    <citation>Surjana D, Halliday GM, Damian DL. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J Nucleic Acids. 2010 Jul 25;2010. pii: 157591. doi: 10.4061/2010/157591.</citation>
    <PMID>20725615</PMID>
  </reference>
  <reference>
    <citation>Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD, Lam EW. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther. 2010 Apr;9(4):844-55. doi: 10.1158/1535-7163.MCT-09-0971. Epub 2010 Apr 6.</citation>
    <PMID>20371709</PMID>
  </reference>
  <reference>
    <citation>McCarthy AR, Sachweh MC, Higgins M, Campbell J, Drummond CJ, van Leeuwen IM, Pirrie L, Ladds MJ, Westwood NJ, La√≠n S. Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner. Mol Cancer Ther. 2013 Apr;12(4):352-60. doi: 10.1158/1535-7163.MCT-12-0900. Epub 2013 Jan 15.</citation>
    <PMID>23322738</PMID>
  </reference>
  <reference>
    <citation>Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA; European Nicotinamide Diabetes Intervention Trial Group. Safety of high-dose nicotinamide: a review. Diabetologia. 2000 Nov;43(11):1337-45. Review.</citation>
    <PMID>11126400</PMID>
  </reference>
  <reference>
    <citation>Gale EA, Bingley PJ, Emmett CL, Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004 Mar 20;363(9413):925-31.</citation>
    <PMID>15043959</PMID>
  </reference>
  <reference>
    <citation>Petley A, Macklin B, Renwick AG, Wilkin TJ. The pharmacokinetics of nicotinamide in humans and rodents. Diabetes. 1995 Feb;44(2):152-5.</citation>
    <PMID>7859933</PMID>
  </reference>
  <reference>
    <citation>Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983 Jun;39(2):499-503.</citation>
    <PMID>6354290</PMID>
  </reference>
  <reference>
    <citation>Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.</citation>
    <PMID>20573926</PMID>
  </reference>
  <reference>
    <citation>Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.</citation>
    <PMID>21783417</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2015</study_first_submitted>
  <study_first_submitted_qc>April 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2015</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chungbuk National University</investigator_affiliation>
    <investigator_full_name>Il Yeong Park, Ph.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>EGFR mutated lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

